HFX iQ has already earned FDA approval in 2022, according to a news release. The spinal cord stimulator uses artificial intelligence combined with high-frequency therapy to help patients with chronic pain. It is indicated for back and leg pain, non-surgical refractory back pain, painful diabetic neuropathy, chronic upper limb and neck pain.
The company plans to launch the system in select European countries in early 2025.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
